{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"500,000,000,000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Phase I: To determine the recommended phase II dose (RP2D) of PRGN-2009 Human Papillomavirus Vaccine (HPV) vaccine alone or in combination with M7824 (MSB0011359C). Recommended Phase 2 Dose, the dose of a drug or drug combination that was identified in a Phase 1 study (dose finding study) that was identified for continued study.","groups":[{"description":"All Participants in phase I who received at least one dose of Monotherapy Human Papillomavirus Vaccine (HPV) vaccine at 1x10\\^11 Viral Particles (VP) and/or plus bintrafusp alfa 1200 mg.","id":"OG000","title":"All Participants in Phase I"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Date treatment consent signed to date off study, approximately 18 months","title":"Phase I: Recommended Phase II Dose of PRGN-2009","type":"PRIMARY","unitOfMeasure":"viral particles (VP)"}